Constructing Practical Pathways for RAASi Management: A Review of Emerging Data
-
18m 16s
-
6m 50s
In this peer-to-peer discussion, Dr Anjay Rastogi (David Geffen School of Medicine UCLA, US) and Dr Shelley Zieroth (University of Manitoba, CA) summarise and distil emerging real-world data on modern practices and approaches to treating hyperkalaemia during RAASi therapy in cardiorenal patients to optimise RAASI therapy.
Key Learning Objectives
- Describe the importance of optimised RAASi therapy in cardiorenal patients
- Recall real-world evidence behind modern RAASi management practices and the utility of novel potassium binder therapy
- Develop a practical approach to optimising hyperkalaemia management through GDMT in real world practice
Target Audience
- Cardiologists
- Heart Failure Specialists
- Nephrologists
- Primary Care Physicians
More from this programme
Part 1
What Do We Know So Far?
Dr Rastogi opens this series by asking Dr Shelley Zieroth to provide an overview on the current sub-optimal use of RAASi, the impact on patients, and the benefit of novel potassium binders in treatment.
| 1 session | |
| What Do We Know So Far? | Watch now |
Part 2
What Does Emerging Data Tell Us?
In this second part, Dr Zieroth invites Dr Rastogi to present key real-world data from the observational ZORA study and discuss his approach to optimising care.
| 1 session | |
| What Does Emerging Data Tell Us? | Watch now |
Part 3
How Might This Impact Clinical Practice?
In this final part, Dr Rastogi and Dr Zieroth discuss lessons from recent data, multi-disciplinary collaboration, implementation of guidelines, the need to ensure RAASi therapy is optimised for patients, and how this prompts a behavioural change in routine practice and impacts patient outcomes.
Faculty Biographies
Anjay Rastogi
Professor and Clinical Chief of Nephrology
Dr Anjay Rastogi is Professor and Clinical Chief of Nephrology at the David Geffen School of Medicine UCLA in Los Angeles, California. Dr Rastogi is recognised as a pioneer in the early treatment of chronic kidney disease to prevent patients’ need to transition to dialysis.
Dr Rastogi is board-certified in Nephrology and has a doctoral degree (PhD) in Pharmacology. He did his Internal Medicine residency and Nephrology fellowship at UCLA; he completed his graduate training under the mentorship of Nobel Laureate Professor Louis Ignarro, also at UCLA. Dr Rastogi is the founding Director of the UCLA Health CORE Kidney Programme. This Programme is based on the CORE values of Clinical Excellence, Outreach, Research, and Education.
Shelley Zieroth
Director, Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.
Comments